



## Introduction

- Ulcerative Colitis (UC) is a chronic autoimmune condition predominately manifesting as colonic inflammation with serious morbidity
- Early intervention with medical therapies can alter the disease course, improving symptoms and reducing the need for hospitalization and surgery
- While patients and providers are increasingly focused on the use and side effects of biologic therapies, older medications such as mesalamine (5-ASA) are still commonly prescribed and can cause idiosyncratic reactions
- We present a case of 5-ASA induced myopericarditis to highlight this rare, life-threatening complication

## **Case Description**


- A 28-year-old male basic military trainee was referred for evaluation of iron deficiency anemia
- Patient reported chronic 2-4 bowel movements daily and hematochezia with wiping. Physical exam was unremarkable
- Labs revealed hemoglobin of 11.6g/dL, iron saturation 15% and ferritin 16ng/mL
- The patient underwent colonoscopy, which demonstrated features consistent with Mayo 2 UC extending from the anus to 30cm (Figure 2), with biopsies confirming chronic active proctitis and colitis
- Patient was started on oral 5-ASA for mildly active left sided UC with good clinical response

### **Contact Information:**


Christopher M. Cowan, MD LTC, MC, USA Division of Gastroenterology & Hepatology Brooke Army Medical Center Christopher.cowan4.mil@army.mil

# Heart Aches with Mesalamine: A Rare Case of Aminosalicylate-induced Myopericarditis in a Basic Military Trainee

Christopher M. Cowan, MD, LTC, MC, USA<sup>1</sup>; Geoffrey A. Bader, MD, Maj, MC, USAF<sup>1</sup> <sup>1</sup>Department of Gastroenterology and Hepatology, Brooke Army Medical Center, Ft. Sam Houston, TX



**Figure 1.** EKG with diffuse T wave elevations consistent with pericarditis



**Figure 2.** Colonoscopy with erythema, vascular drop out small erosions, and contact friability

The views expressed herein are those of the authors and do not reflect the official policy or position of Brooke Army Medical Center, the Department of Defense, or any agencies under the U.S. Government.

Figure 3. Cardiac MRI with diffuse, patchy left ventricular gadolinium enhancement

- peptide of 1888pg/mL

- therapy
- weeks of treatment

#### **References:**

1. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, on behalf of the AGA Institute Clinical Guidelines Committee. Gastroenterology 2020; 158: 1450-1461. 2. Mesalamine- induced Myopericarditis: A Case Report and Literature Review. Taha ME, Abdalla A, Al-Khafaji J, Malik S. Cardiology Research 2019; 10(1): 59-62. 3. ACG Clinical Guideline: Ulcerative Colitis in Adults. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. The American Journal of Gastroenterology 2019; 114: 384-413.



## **Case Description Continued**

Three weeks after starting treatment, patient presented to the Emergency Department with pleuritic chest pain, worse with exertion

Electrocardiogram (EKG) showed diffusely elevated T waves (Figure 1)

Labs revealed a troponin of 0.03ng/mL and proBrain natriuretic

Patient was admitted to the hospital and ruled out for alternative infectious and autoimmune etiologies

Cardiac MRI demonstrated diffuse, patchy ventricular enhancement and a reduced left ventricular systolic function (Figure 3)

Patient was diagnosed with 5-ASA induced myopericarditis and discharged on colchicine and prednisone with good clinical response

## Discussion

Myopericarditis is a rare, potentially lethal complication of 5-ASA

The pathophysiology of 5-ASA related cardiac manifestations are poorly understood, with reactions typically seen within the first 1-4

Diagnosis of 5-ASA pericarditis is clinical without distinguishing features from other causes of pericarditis

Most patients improve dramatically with discontinuation and lifelong avoidance of mesalamine, with the role for steroids and antiinflammatory therapy somewhat controversial

Our case serves to remind clinicians of this serious side effect and the importance of thorough risk-benefits counseling for any UC treatment